Jun 18, · NBA chief executive Willy Tonui said scientific analysis was still going on. He invited comments from professional groups and the public before a final decision is reached on the product. “The application is undergoing a science-based review process by NBA, regulatory agencies and independent experts.
“Genetic technologies such as gene drive hold great promise, and as an emerging area of science, they require a rigorous approach,” said Willy Tonui, Ph.D., EBS, GeneConvene partner and former CEO of Kenya’s National Biosafety Authority.
At the National Biosafety Authority (NBA), CEO Willy Tonui claims media hysteria and inaccurate reporting are to blame for resistance to GM technology, arguing the NBA maintains stringent guidelines about GM seeds in Kenya. Referring to the plans to allow GM maize seeds in by 2017, Tonui said
Chair: Willy Tonui (Kenya Medical Research Institute, Kenya) Rapporteur: Jennifer Gaudioso (Sandia National Laboratories, United States) • Maintenance, certification and cost-saving issues for BSL-3 labs in southeast Asia. Page 107 Share Cite. Suggested Citation:"Appendix A: Workshop Agenda." National Academy of Sciences and National Research ...
Willy Tonui, Environmental Health Services Ltd., Kenya, shared the experiences of regulators with a focus on a case study from Kenya. He spoke on requirements of international conventions, including those being made at CBD COP 14, which are relevant for many developing countries.
Sep 22, · “That’s an ongoing project at the KALRO Centre in Alupe, Busia,” said Willy Tonui, the NBA chief executive. GMO banana research has been going on for years, targeting the bacterial wilt disease.
Jan 27, · Willy Tonui, National Biosafety Authority chief executive officer, said the mark will be used on all approved GMOs in Kenya. This is despite the cabinet ban on such products and the fact that...
Willy Tonui, Kenya Centre for Biotechnology Research and Development, Kenya Medical Research Institute Project: Evaluation of Leishmania donovani derived lipophosphoglycan as a candidate vaccine against visceral leishmaniasis in murine models. Fall Small Grant Awardees.